loading
Schlusskurs vom Vortag:
$23.15
Offen:
$23.55
24-Stunden-Volumen:
504.62K
Relative Volume:
0.54
Marktkapitalisierung:
$1.55B
Einnahmen:
$13.05M
Nettoeinkommen (Verlust:
$-60.54M
KGV:
-19.91
EPS:
-1.16
Netto-Cashflow:
$-37.82M
1W Leistung:
+0.96%
1M Leistung:
-2.94%
6M Leistung:
-56.85%
1J Leistung:
-44.86%
1-Tages-Spanne:
Value
$22.90
$24.25
1-Wochen-Bereich:
Value
$22.55
$24.25
52-Wochen-Spanne:
Value
$22.48
$71.71

Janux Therapeutics Inc Stock (JANX) Company Profile

Name
Firmenname
Janux Therapeutics Inc
Name
Telefon
(858) 751-4493
Name
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Name
Mitarbeiter
91
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-06
Name
Neueste SEC-Einreichungen
Name
JANX's Discussions on Twitter

Vergleichen Sie JANX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
JANX
Janux Therapeutics Inc
23.10 1.55B 13.05M -60.54M -37.82M -1.16
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.20 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
525.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.09 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
551.22 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.07 28.51B 3.81B -644.79M -669.77M -6.24

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-03 Bestätigt BTIG Research Buy
2024-12-03 Bestätigt H.C. Wainwright Buy
2024-11-22 Eingeleitet Leerink Partners Outperform
2024-10-24 Eingeleitet UBS Buy
2024-09-06 Eingeleitet Stifel Buy
2024-05-30 Eingeleitet Scotiabank Sector Perform
2024-03-21 Eingeleitet BTIG Research Buy
2024-03-20 Eingeleitet Cantor Fitzgerald Overweight
2023-04-06 Eingeleitet Wedbush Outperform
2022-11-14 Eingeleitet William Blair Outperform
Alle ansehen

Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten

pulisher
Jun 18, 2025

Janux Therapeutics Becomes Oversold (JANX) - Nasdaq

Jun 18, 2025
pulisher
Jun 17, 2025

Closing Figures Unveiled: Janux Therapeutics Inc (JANX) Drop -5.18, Closes at 23.61 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Janux Therapeutics, Inc. (JANX) Stock Analysis: Biotechnology Pioneer with 256.30% Potential Upside - DirectorsTalk Interviews

Jun 17, 2025
pulisher
Jun 15, 2025

Where are the Opportunities in (JANX) - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 13, 2025

Janux Therapeutics reports annual meeting results By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Janux Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Janux Therapeutics reports annual meeting results - Investing.com

Jun 13, 2025
pulisher
Jun 11, 2025

Advanced Renal Cell Carcinoma Pipeline 2025: In-depth Clinical - openPR.com

Jun 11, 2025
pulisher
Jun 11, 2025

Equities Analysts Issue Forecasts for JANX FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 08, 2025

California State Teachers Retirement System Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Janux Therapeutics (NASDAQ:JANX) Shares Up 7.9% – Time to Buy? - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Janux Therapeutics: Advancing Tumor-Targeted Immunotherapy with Innovative T Cell Platform - majiroxnews.com

Jun 05, 2025
pulisher
Jun 03, 2025

Janux Therapeutics, Inc. (NASDAQ:JANX) Position Lifted by Ameriprise Financial Inc. - Defense World

Jun 03, 2025
pulisher
May 30, 2025

SA Asks: Which oncology companies are attractive M&A targets? - Seeking Alpha

May 30, 2025
pulisher
May 30, 2025

Nuveen Asset Management LLC Sells 39,145 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

May 30, 2025
pulisher
May 28, 2025

Millennium Management LLC Invests $6.22 Million in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

May 28, 2025
pulisher
May 27, 2025

BNP Paribas Financial Markets Purchases New Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

May 27, 2025
pulisher
May 23, 2025

When the Price of (JANX) Talks, People Listen - news.stocktradersdaily.com

May 23, 2025
pulisher
May 20, 2025

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Buy” by Analysts - Defense World

May 20, 2025
pulisher
May 20, 2025

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com

May 20, 2025
pulisher
May 20, 2025

How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com

May 20, 2025
pulisher
May 15, 2025

Janux appoints Janeen Doyle chief corporate, business development officer - TipRanks

May 15, 2025
pulisher
May 15, 2025

Janux Therapeutics (JANX) Welcomes New Chief Corporate and Busin - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Janux Therapeutics (JANX) Welcomes New Chief Corporate and Business Development Officer | JANX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer - Bluefield Daily Telegraph

May 15, 2025
pulisher
May 15, 2025

Northern Trust Corp Buys 42,302 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

May 15, 2025
pulisher
May 15, 2025

Cantor Fitzgerald Brokers Raise Earnings Estimates for JANX - Defense World

May 15, 2025
pulisher
May 15, 2025

Q2 EPS Estimate for Janux Therapeutics Boosted by Analyst - Defense World

May 15, 2025
pulisher
May 14, 2025

Janux Therapeutics Reports Increased Q1 Losses Amid R&D Expansion - TipRanks

May 14, 2025
pulisher
May 13, 2025

Trend Tracker for (JANX) - news.stocktradersdaily.com

May 13, 2025
pulisher
May 12, 2025

Leerink cuts Janux Therapeutics price target to $89, keeps Outperform By Investing.com - Investing.com India

May 12, 2025
pulisher
May 10, 2025

Janux Therapeutics Inc (JANX) Gets a Hold from Scotiabank - The Globe and Mail

May 10, 2025
pulisher
May 09, 2025

Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc - TipRanks

May 09, 2025
pulisher
May 09, 2025

Janux Therapeutics price target lowered to $36 from $41 at Scotiabank - TipRanks

May 09, 2025
pulisher
May 09, 2025

Janux Therapeutics (JANX) Reports Q1 EPS Loss, Maintains Strong Cash Position - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Scotiabank Adjusts Janux Therapeutics (JANX) Price Target Amid T - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position - TipRanks

May 09, 2025
pulisher
May 09, 2025

Decoding Janux Therapeutics Inc (JANX): A Strategic SWOT Insight - GuruFocus

May 09, 2025
pulisher
May 08, 2025

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - BioSpace

May 08, 2025
pulisher
May 08, 2025

Janux Therapeutics Inc: Undervalued Growth Potential Amid Recent Stock Pullback - TipRanks

May 08, 2025
pulisher
May 08, 2025

Janux Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025
pulisher
May 08, 2025

Janux Therapeutics (JANX) Advances Clinical Trials for JANX007 | JANX Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Janux Therapeutics reports Q1 EPS (38c), consensus (39c) - TipRanks

May 08, 2025
pulisher
May 08, 2025

BRIEF-Janux Therapeutics Q1 Basic EPS USD -0.38 - TradingView

May 08, 2025
pulisher
May 08, 2025

Buy Rating for Janux Therapeutics Inc. Driven by Strategic Advancements in Prostate Cancer Treatment with JANX007 - TipRanks

May 08, 2025
pulisher
May 06, 2025

Janux Therapeutics (NASDAQ:JANX) Shares Gap Down After Insider Selling - Defense World

May 06, 2025
pulisher
May 06, 2025

Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation - TipRanks

May 06, 2025
pulisher
May 06, 2025

Janux commences Phase Ib studies in trial for prostate cancer treatment - Clinical Trials Arena

May 06, 2025
pulisher
May 05, 2025

Buy Rating for Janux Therapeutics Inc: Promising Clinical Trial Results and Positive Outlook for JANX007 - TipRanks

May 05, 2025
pulisher
May 05, 2025

Janux Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView

May 05, 2025

Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Janux Therapeutics Inc-Aktie (JANX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Meyer Andrew Hollman
Chief Business Officer
May 01 '25
Sale
32.03
3,333
106,745
82,139
$20.66
price up icon 0.78%
$36.03
price up icon 0.45%
$21.28
price up icon 3.30%
$100.64
price up icon 1.16%
$106.47
price down icon 0.23%
biotechnology ONC
$242.07
price up icon 0.36%
Kapitalisierung:     |  Volumen (24h):